Promentis Pharmaceuticals, founded in Milwaukee, United States, is a privately-held biopharmaceutical company with a core mission to develop innovative therapies for neuropsychiatric disorders. The company's vision is to redefine what is possible in the treatment of these conditions. Promentis focuses on addressing unmet medical needs, with its first indication being trichotillomania, a prevalent disorder lacking approved therapies. The company leverages alterations in glutamate signaling within brain regions implicated in urge control to develop its treatments.

Notable individuals affiliated with Promentis Pharmaceuticals include experienced professionals from the biopharmaceutical industry, though specific names are not provided. The company has attracted significant interest from investors due to its pioneering approach to neuropsychiatric disorders. Key achievements include advancing its lead drug candidate through critical stages of development, positioning itself as a potential leader in the neuropsychiatric therapeutic market. Promentis Pharmaceuticals' impact lies in its commitment to providing effective treatments for conditions that currently have limited or no therapeutic options.